Nierentransplantation

ZUSAMMENFASSUNG

Über 60 Jahre nach der ersten langfristig erfolgreichen Nierentransplantation stellt diese heutzutage ein sicheres, etabliertes und effektives Therapiekonzept in der Versorgung terminal dialysepflichtiger Patienten dar. Grundlegende Voraussetzungen für eine erfolgreiche Nierentransplantation sind die Entschlüsselung relevanter immunologischer Fragen, die zunehmenden Möglichkeiten einer optimierten, auf den individuellen Patienten und sein immunologisches und nichtimmunologisches Risikoprofil abgestimmten immunsuppressiven Therapie und eine konsequente, qualifizierte Nachsorge. Gleichwohl gefährden der anhaltende und sich aggravierende Mangel an Spenderorganen und die damit einhergehende Zunahme an Wartezeit nicht nur die erreichbaren Erfolge nach Nierentransplantation, sondern in direkter Konsequenz auch das Leben betroffener Patienten.

• Literatur

• 1 Andrews PA, Burnapp L. British Transplantation Society/Renal Association UK Guidelines for Living Donor Kidney Transplantation 2018: Summary of Updated Guidance. Transplantation 2018; 102: e307 doi:10.1097/TP.0000000000002253
• 2 Davis CL. Preemptive transplantation and the transplant first initiative. Curr Opin Nephrol Hypertens 2010; 19: 592-597 doi:10.1097/MNH.0b013e32833e04f5
• 3 Dudley C, Harden P. Renal Association Clinical Practice Guideline on the assessment of the potential kidney transplant recipient. Nephron Clin Pract 2011; 118 (Suppl. 01) c209-c224 doi:10.1159/000328070
• 4 Wolfe RA, Ashby VB, Milford EL. et al Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730 doi:10.1056/NEJM199912023412303
• 5 Tonelli M, Wiebe N, Knoll G. et al Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011; 11: 2093-2109 doi:10.1111/j.1600-6143.2011.03686.x
• 6 Lloveras J, Arcos E, Comas J. et al A paired survival analysis comparing hemodialysis and kidney transplantation from deceased elderly donors older than 65 years. Transplantation 2015; 99: 991-996 doi:10.1097/TP.0000000000000474
• 7 Pérez-Sáez MJ, Montero N, Redondo-Pachón D. et al Strategies for an Expanded Use of Kidneys From Elderly Donors. Transplantation 2017; 101: 727-745 doi:10.1097/TP.0000000000001635
• 8 Orandi BJ, James NT, Hall EC. et al Center-level variation in the development of delayed graft function after deceased donor kidney transplantation. Transplantation 2015; 99: 997-1002 doi:10.1097/TP.0000000000000450
• 9 Melih KV, Basak B, Mustafa C. et al Incidence, Risk Factors, and Outcomes of Delayed Graft Function in Deceased Donor Kidney Transplantation. Transplant Proc 2019; 51: 1096-1100 doi:10.1016/j.transproceed.2019.02.013
• 10 Kasiske BL, Zeier MG, Chapman JR. et al Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77: 299-311 doi:10.1038/ki.2009.377
• 11 Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 03) S1-S155 doi:10.1111/j.1600-6143.2009.02834.x
• 12 Ekberg H, Tedesco-Silva H, Demirbas A. et al ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575 doi:10.1056/NEJMoa067411
• 13 Thomusch O, Wiesener M, Opgenoorth M. et al Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet 2016; 388: 3006-3016 doi:10.1016/S0140-6736(16)32187-0
• 14 Hauch A, John M, Smith A. et al Generics: are all immunosuppression agents created equally?. Surgery 2015; 158: 1049-1054 doi:10.1016/j.surg.2015.05.024
• 15 Haller MC, Royuela A, Nagler EV. et al Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2016: CD005632 doi:10.1002/14651858.CD005632.pub3
• 16 Pascual J, Berger SP, Witzke O. et al TRANSFORM Investigators. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol 2018; 29: 1979-1991 doi:10.1681/ASN.2018010009
• 17 Sommerer C, Suwelack B, Dragun D. et al An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int 2019; 96: 231-244 doi:10.1016/j.kint.2019.01.041
• 18 Malvezzi P, Jouve T, Rostaing L. Costimulation Blockade in Kidney Transplantation: An Update. Transplantation 2016; 100: 2315-2323 doi:10.1097/TP.0000000000001344
• 19 Durrbach A, Pestana JM, Pearson T. et al A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557 doi:10.1111/j.1600-6143.2010.03016.x
• 20 Vincenti F, Charpentier B, Vanrenterghem Y. et al A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546 doi:10.1111/j.1600-6143.2009.03005.x
• 21 Rostaing L, Vincenti F, Grinyo J. et al Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13: 2875-2883 doi:10.1111/ajt.12460
• 22 Ristov J, Espie P, Ulrich P. et al Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant 2018; 18: 2895-2904 doi:10.1111/ajt.14872
• 23 Schiffer L, Hartleib-Otto M, Lerch C. et al [Challenges in Long-Term Follow-Up Care of Patients After Kidney Transplantation in Specialized Transplant Centers]. Gesundheitswesen 2019 Jun 11. doi:10.1055/a-0883-5218. [Epub ahead of print]
• 24 Comai G, Ravaioli M, Baraldi O. et al Treatment of Acute Antibody-Mediated Rejection. Contrib Nephrol 2017; 190: 156-167 doi:10.1159/000468962
• 25 Eskandary F, Regele H, Baumann L. et al A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol 2018; 29: 591-605 doi:10.1681/ASN.2017070818
• 26 Choi J, Aubert O, Vo A. et al Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant 2017; 17: 2381-2389 doi:10.1111/ajt.14228
• 27 Kasiske BL, Zeier MG, Chapman JR. et al Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77: 299-311 doi:10.1038/ki.2009.377
• 28 Cross NB, Webster AC, Masson P. et al Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7-18 doi:10.1097/TP.0b013e3181a9e960
• 29 Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303-1309 doi:10.1038/ki.2014.31
• 30 Holdaas H, Jardine A. Acute renal allograft rejections, a role for statins?. Minerva Urol Nefrol 2003; 55: 111-119
• 31 Palmer SC, Navaneethan SD, Craig JC. et al HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2014: CD005019 doi:10.1002/14651858.CD005019.pub4
• 32 van Leeuwen MT, Grulich AE, Webster AC. et al Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009; 114: 630-637 doi:10.1182/blood-2009-02-202507
• 33 Cunningham J. Posttransplantation bone disease. Transplantation 2005; 79: 629-634 doi:10.1097/01.tp.0000149698.79739.ef
• 34 Kataria A, Magoon S, Makkar B. et al Machine perfusion in kidney transplantation. Curr Opin Organ Transplant 2019; 24: 378-384 doi: 10.1097/MOT.0000000000000675
• 35 Nangia G, Borges K, Reddy KR. Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option. J Viral Hepat 2019; 26: 1362-1371 doi:10.1111/jvh.13130
• 36 de Vera ME, Volk ML, Ncube Z. et al Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia. Am J Transplant 2018; 18: 2451-2456 doi:10.1111/ajt.15031
• 37 Cooper DKC, Gaston R, Eckhoff D. et al Xenotransplantation-the current status and prospects. Br Med Bull 2018; 125: 5-14 doi:10.1093/bmb/ldx043